Kidney transplant
Conditions
Interventions
EC-MPS + tacrolimus + glucocorticoids:At least 6 months after kidney transplantation, the recipients should be treated with MMF as an antimetabolite drug, and all were treated with a triple immunosupp
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Stable kidney transplant recipients who have received allogeneic for the first time (>= 6 months after kidney transplantation), regardless of age and gender; (2) Routine use of "MMF+tacrolimus (TAC)+glucocorticoid" triple immunosuppression regimen for at least 4 consecutive weeks before enrollment; (3) Patients who need to stop MMF due to gastrointestinal adverse reactions or investigator evaluation, change to domestic EC-MPS (Reyirong) and plan to use it continuously for at least 1 year;
Exclusion criteria
Exclusion criteria: (1) Multi-organ recipients, such as those with heart, lung, liver and other organ transplants; (2) Those who are allergic to MPA, such as MMF, EC-MPS or preparation components (hypersensitivity); (3) Women who are pregnant, lactating or planning to become pregnant; (4) severe/uncontrolled concomitant infections or other serious medical problems; (5) Active bacterial, viral, or fungal infection; (6) Neutropenia (ANC <1.3×10^3/µL) (7) Patients who are judged by the investigator to be unsuitable for inclusion in this study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastrointestinal symptom score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of gastrointestinal reactions;Treatment failure rate; | — |
Countries
China
Contacts
Public ContactXiaoming Ding
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed